Analystreport

Dermira, Inc. (NASDAQ: DERM) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $43.00 price target on the stock, up previously from $40.00.

Journey Medical Corporation  (DERM) 
Last journey medical corporation earnings: 11/5 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.dermira.com